The question
Selank has human research, including a small comparison with another anxiety medicine. That is more informative than a mechanism claim alone, but it does not settle whether Selank is an effective, safe substitute for established care. The distinction becomes clear when reading the publicly available abstract rather than a promotional paraphrase. Original study record.
What the 62-patient report says
A 2008 Russian-language paper studied patients with generalized anxiety disorder and neurasthenia. Thirty received Selank and 32 received medazepam. Investigators used Hamilton, Zung and Clinical Global Impression assessments and measured serum enkephalin activity. The abstract describes similar anxiety effects and additional effects on fatigue-related symptoms and stimulation with Selank. PubMed indexes the paper as a randomized controlled trial. Zozulia and colleagues.
Those are the authors' reported findings. This article used the indexed abstract, not a full independent appraisal of the Russian-language paper. The abstract does not provide the detailed effect sizes, confidence intervals or allocation procedures needed for a complete comparison. Missing information in an abstract should be labeled as missing, not replaced with guessed methods.
Why “similar” does not establish equivalence
A study can report similar observed results without demonstrating that two treatments are clinically interchangeable. A formal equivalence or noninferiority claim needs a defined acceptable difference and an analysis precise enough to assess it. Simply failing to detect a difference does not establish that the difference is acceptably small.
An active comparator also answers a different question from a placebo comparison. It can help compare treatments, but the design and analysis still determine what conclusions follow. The presence of a familiar comparison medicine should not act as a shortcut around those details.
Mechanism findings answer another question
A separate 2018 laboratory study investigated Selank and GABA binding using receptor-focused methods. It reported effects consistent with modulation of that system. It was a molecular-mechanism investigation, not another patient trial demonstrating improved anxiety outcomes. Original mechanistic study.
This is where evidence summaries can become misleading: a clinical abstract and a laboratory mechanism are placed next to each other, then treated as if they jointly prove a broad benefit. A plausible mechanism can help explain a hypothesis. It cannot fill gaps in a clinical comparison or establish long-term safety.
What US readers should keep separate
FDA's current safety assessment identifies inadequate information about administered Selank acetate and potential immune-reaction concerns. FDA assessment, checked September 25, 2026. Compounded drugs are not FDA-approved products. FDA compounding guidance. This article does not establish an FDA-approved Selank treatment.
The useful next question is not whether a compound has any human paper, but whether the paper supports the precise claim being made. Check the preparation, population, comparator, measured change and follow-up. See what peptides are for terminology.
Related reading
Continue with the Semax stroke-rehabilitation study.
Sources & further reading
Research context last reviewed September 25, 2026. Last updated October 6, 2026. Educational reading, not individual medical advice. How this article was prepared.
